Health & Fitness

Grover Eye Hospital introduces Lumenis M22 Optimal Pulse Technology for Dry Eye in Chandigarh

Kaumimarg Bureau | June 04, 2018 02:37 PM
Grover Eye Hospital introduces Lumenis M22 Optimal Pulse Technology for Dry Eye in Chandigarh

 


Chandigarh, Grover Eye Laser & ENT hospital Chandigarh, has introduced for the first time in the region the Lumenis M22 Optimal Pulse Technology (OPT) for treatment of dry eyes. This latest eye care technology is a great revolution in the treatment of eye lid MGD and Dry Eyes.

Lumenis Inc is the world’s largest energy-based medical device company and is renowned for technological breakthroughs ophthalmic lasers and a long list of industry gold standards.

Studies show that humans generally blink about 22 times a minute. But when we concentrate on a computer screen or a smart phone or even while driving, the rate goes down to five or seven blinks per minute. If this tear film does not spread sufficiently across the eye, it can lead to dryness and irritation. In addition many other conditions also cause Dry Eyes, the number one cause of eye disorders today.

Dr Rohit Grover, Senior Ophthalmologist said “Dry eye is most common problem in eye OPD patients today. So far only eye drops gave some temporary relief. With the introduction of innovative M22 OPT technology, we are quite confident that we will be able to give the best treatment for Dry Eye to the patients in India also. Patients with dry eye often complain of multiple symptoms like pain, heaviness, foreign body sensation, redness, light sensitivity and reflex watering due to corneal irritation. They also have feeling of burning eyes, stinging, grittiness and tired eyes.”

Mr. Dharmendra Mistry Country Head of Lumenis India, said “Till now, there was no treatment or any permanent solution available for dry eyes. Our path breaking technology will help address the growing dry eye disease among thousands of people”.

“The company has also developed a practice enhancement program for clinics as it foresees rapid increase in demand for dry eye treatment with OPT technology. We continue to invest in our training and education platforms to ensure that increasing number of patients benefit from the latest OPT technology,” Mr Mistry, said.


Meibomian Gland dysfunction (MGD) is one of the leading causes of dry eye disease (DED), affecting millions of people worldwide. Optimal pulse technology from Lumenis has emerged as the most effective alternative for patients, leading to significant improvement in ocular surface quality, eye lid gland function and dry eye symptoms.


Mr. Navkaran Singh Chimni, Senior Director- Medical Business (India & South Asia), Lumenis said, “Lumenis Inc is known for inventing the first ever laser for ophthalmic use and we are proud further to introduce yet another revolutionary technology M22 “OPT” which helps us in addressing the Dry Eye condition which is increasing day by day due to the lifestyle changes and strong dependency on the smart phones and laptops.

The Lumenis M22 OPT is an excellent technology for treating eyelid inflammation. OPT is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombolysis. A major source of inflammation threatening the eyelids is then removed. It treats the root cause of the problem, provides immediate relief, a safe and comfortable, fast ‘lunch time treatment’ and improves the skin appearance too.

Have something to say? Post your comment